Sarepta Therapeutics Inc
(BSP:S1RP34)
R$
37.72
-0.52 (-1.36%)
Market Cap: 72.06 Bil
Enterprise Value: 73.29 Bil
PE Ratio: 78.90
PB Ratio: 9.50
GF Score: 79/100 Sarepta Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 11, 2022 / 04:20PM GMT
Release Date Price:
R$15.94
(-5.62%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
So thanks for joining us at the Bank of America Healthcare Conference. This is Day 2 for us here in Las Vegas. I'm Tazeen Ahmad one of the Senior Executive Biotech Analyst here at the bank. It's my pleasure to have our next presenting company with us, Sarepta Therapeutics. Presenting for Sarepta will be CEO, Doug Ingram. So Doug, welcome. I think this will be your first time for participating at our conference as CEO of Sarepta. So thanks for joining us.
Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director
It is. I'm great -- I am excited to be here.
Questions & Answers
Tazeen Ahmad;Douglas S. Ingram
BofA Securities, Research Division - MD in Equity Research & Research Analyst
So maybe we could start off with a quick 2-minute overview of the company, what's been going on with Sarepta and then we can go into more detailed Q&A if that makes sense for you?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot